Advertisement

Topics

Sage scores good but not great P3 postpartum depression drug results

04:20 EST 10 Nov 2017 | Pharmafile

Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant results in the treatment of postpartum depression (PPD).

This rapid and immediate rise suggests that there is significant faith that its drug could become a major seller for the 10 to 20% of women affected by the condition.

Sage plans on filing with the FDA for a NDA for the drug but there are significant questions over just how effective the treatment is; these questions may well give the FDA pause for thought over the drug.

read more

Original Article: Sage scores good but not great P3 postpartum depression drug results

NEXT ARTICLE

More From BioPortfolio on "Sage scores good but not great P3 postpartum depression drug results"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...